better therapeutics (f/k/a farewell) is developing prescription digital therapeutics for treating chronic disease. its innovative solution combines software, human coaching augmented by artificial intelligence, and advanced analytics to address the behaviors at the root cause of most chronic conditions, in a manner that can scale rapidly to address millions of covered lives. better’s digital therapeutics are based on well-established evidence, fit within existing clinical treatment guidelines, and can be used with or without other interventions. better believes non-drug treatment options are essential to reducing the unnecessary health and cost burden of chronic disease on individuals, payers, and the nation.
Company profile
Ticker
BTTX
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mountain Crest Acquisition Corp II
SEC CIK
BTTX stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
21 Mar 24
8-K
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
21 Mar 24
424B3
Prospectus supplement
15 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
424B3
Prospectus supplement
14 Mar 24
8-K
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
14 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
RW
Registration withdrawal request
1 Mar 24
S-1/A
IPO registration (amended)
6 Feb 24
Transcripts
BTTX
Earnings call transcript
2023 Q3
9 Nov 23
BTTX
Earnings call transcript
2023 Q2
9 Aug 23
BTTX
Earnings call transcript
2023 Q1
11 May 23
BTTX
Earnings call transcript
2022 Q4
30 Mar 23
BTTX
Earnings call transcript
2022 Q3
14 Nov 22
BTTX
Earnings call transcript
2022 Q2
14 Aug 22
BTTX
Earnings call transcript
2022 Q1
13 May 22
Latest ownership filings
4
DAVID P PERRY
13 Feb 24
SC 13G/A
MMCAP International Inc. SPC
13 Feb 24
SC 13D/A
David P. Perry 2015 Trust
12 Feb 24
SC 13D/A
David P. Perry 2015 Trust
25 Jan 24
4
DAVID P PERRY
10 Jan 24
4
DAVID P PERRY
20 Dec 23
4
Richard H Carmona
20 Dec 23
4
RISA J LAVIZZO-MOUREY
20 Dec 23
4
Kristin Wynholds
20 Dec 23
4
Geoffrey M. Parker
20 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.60 mm | 6.60 mm | 6.60 mm | 6.60 mm | 6.60 mm | 6.60 mm |
Cash burn (monthly) | (no burn) | 1.31 mm | 1.95 mm | 2.63 mm | 1.98 mm | 2.17 mm |
Cash used (since last report) | n/a | 8.69 mm | 12.97 mm | 17.46 mm | 13.15 mm | 14.43 mm |
Cash remaining | n/a | -2.09 mm | -6.37 mm | -10.87 mm | -6.55 mm | -7.83 mm |
Runway (months of cash) | n/a | -1.6 | -3.3 | -4.1 | -3.3 | -3.6 |
Institutional ownership, Q2 2023
34.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 18 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.19 bn |
Total shares | 17.42 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
David P. Perry 2015 Trust | 11.80 mm | $14.39 mm |
Appelbaum, or his successor | 2.41 mm | $25.10 mm |
Mountain Crest Capital | 1.39 mm | $2.03 mm |
Farallon Capital Partners | 751.76 k | $0.00 |
Vanguard | 438.48 k | $473.56 mm |
Farallon Capital Management | 330.62 k | $357.07 mm |
Geode Capital Management | 121.72 k | $131.46 mm |
BLK Blackrock | 90.39 k | $97.62 mm |
STT State Street | 45.20 k | $48.82 mm |
NTRS Northern Trust | 16.70 k | $18.04 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 24 | Perry David P | Common Stock | Grant | Acquire A | No | No | 0.1905 | 839,895 | 160.00 k | 2,416,634 |
9 Jan 24 | Perry David P | Common Stock | Grant | Acquire A | No | No | 0.1699 | 1,471,453 | 250.00 k | 1,576,739 |
18 Dec 23 | Mark A. Berman | Common Stock | Grant | Acquire A | No | No | 0 | 25,362 | 0.00 | 448,140 |
18 Dec 23 | Karbe Frank | Common Stock | Grant | Acquire A | No | No | 0 | 62,500 | 0.00 | 526,516 |
18 Dec 23 | Elder Granger | Common Stock | Grant | Acquire A | No | No | 0 | 3,750 | 0.00 | 39,601 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
15 Mar 24
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session
15 Mar 24
12 Health Care Stocks Moving In Friday's Intraday Session
15 Mar 24
Nasdaq Down Over 100 Points; Hibbett Reports Downbeat Sales
15 Mar 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
15 Mar 24
Press releases
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
14 Mar 24
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
5 Mar 24
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
4 Mar 24
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
1 Mar 24
Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease
26 Feb 24